Skip to main content

Redx hails progress

Redx hails progress

DRUG development company Redx Pharma has hailed a year of progress as it released its first full year results since its AIM-listing last March.

Despite pre-tax losses more than doubling from £4.3m to £8.8m, founder and chief executive Dr Neil Murray said the board is “very confident” in the prospects for the business.

“We’ve made fantastic progress across the pipeline, it’s really maturing very well and we expect four of our programmes to be in clinical trials by the end of 2016 or early 2017.”

See the article in full at